{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:29:11Z","timestamp":1789190951339,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lipoprotein(a) [Lp(a)] is one of the residual risk factors for cardiovascular disease (CVD) in the setting of optimal low-density lipoprotein cholesterol (LDL-C). The association between Lp(a) and CVD is still in the exploratory phase, with few studies indicating a causal connection between Lp(a) and various CVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Lp(a) (<jats:italic>n<\/jats:italic>\u2009=\u2009377,590) was a genome-wide association study (GWAS) based on European populations from Neale Lab. Large GWAS datasets for CVD, including aortic aneurysm(AA) (<jats:italic>n<\/jats:italic>\u2009=\u2009209,366), atrial fibrillation(AF) (<jats:italic>n<\/jats:italic>\u2009=\u20091,030,836), coronary heart disease(CHD) (<jats:italic>n<\/jats:italic>\u2009=\u2009361,194), secondary hypertension(HBP) (<jats:italic>n<\/jats:italic>\u2009=\u2009164,147), heart failure(HF) (<jats:italic>n<\/jats:italic>\u2009=\u2009208,178), ischemic stroke (IS) (<jats:italic>n<\/jats:italic>\u2009=\u2009218,792), large artery atherosclerosis stroke(ISL) (<jats:italic>n<\/jats:italic>\u2009=\u2009150, 765), small vessel stroke(ISS) (<jats:italic>n<\/jats:italic>\u2009=\u2009198,048), lacunar stroke(LIS) (<jats:italic>n<\/jats:italic>\u2009=\u2009225,419), and pulmonary embolism(PE) (<jats:italic>n<\/jats:italic>\u2009=\u2009218,413) were also based on European populations. We performed separate univariate two-sample Mendelian randomization (MR) analysis for Lp(a) and CVD as described above. We evaluated this connection mainly using the random-effects inverse variance weighted technique(IVW1) with a 95% confidence interval (CI) for the odds ratio (OR). This was supplemented by MR-Egger, weighted median, maximum likelihood, penalized weighted median, and fixed-effects inverse variance weighted methods. MR-PRESSO offers another means of statistical detection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our two-sample MR, which was predominately based on IVW1, revealed a causal relationship between Lp(a) and AA (OR\u2009=\u20091.005, 95%CI: 1.001\u20131.010, <jats:italic>P<\/jats:italic>\u2009=\u20090.009), CHD (OR\u2009=\u20091.003, 95%CI 1.001\u20131.004, <jats:italic>P<\/jats:italic>\u2009=\u20090.010), and ISL (OR\u2009=\u20091.003, 9 5%CI 1.002\u20131.004, <jats:italic>P<\/jats:italic>\u2009=\u20099.50E\u221211), in addition, there is no causal association with AF, HBP, HF, IS, ISS, LIS, or PE. Similar conclusions were reached by the MR-PRESSO method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This MR study suggested a causal relationship between Lp(a) and CHD, AA, and ISL, but not associated with AF, HF, IS, LIS, ISS, HBP, or PE. Our work further verifies the association between Lp(a) and various CVD, resulting in improved Lp(a) management and a reduction in the prevalence of CVD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00825-6","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T09:03:04Z","timestamp":1666861384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Shiyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-5462","authenticated-orcid":false,"given":"Chang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enze","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"10","key":"825_CR1","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, et al. Heart disease and stroke statistics-2019 update a report from the american heart association. Circulation. 2019;139(10):E56\u2013528.","journal-title":"Circulation"},{"issue":"10159","key":"825_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789\u2013858.","journal-title":"Lancet"},{"issue":"1","key":"825_CR3","first-page":"76","volume":"103","author":"RC Maranhao","year":"2014","unstructured":"Maranhao RC, et al. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76\u201383.","journal-title":"Arq Bras Cardiol"},{"issue":"12","key":"825_CR4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","volume":"77","author":"S Tsimikas","year":"2021","unstructured":"Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a) JACC focus seminar 2\/4. J Am Coll Cardiol. 2021;77(12):1576\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"825_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2261-13-7","volume":"21","author":"C Li","year":"2021","unstructured":"Li C, et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104\u00a0mg\/dL. BMC Cardiovasc Disord. 2021;21(1):7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"825_CR6","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2022;42(1):E48\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"825_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama-J Am Med Assoc. 2009;302(4):412\u201323.","journal-title":"Jama-J Am Med Assoc"},{"issue":"11","key":"825_CR8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","volume":"61","author":"PR Kamstrup","year":"2013","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme Lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"825_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population. Circulation. 2008;117(2):176\u201384.","journal-title":"Circulation"},{"issue":"19","key":"825_CR10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, et al. Apolipoprotein(a) Isoforms and the risk of vascular disease systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"825_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S0002-8703(98)70151-6","volume":"136","author":"Y Igarashi","year":"1998","unstructured":"Igarashi Y, et al. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Am Heart J. 1998;136(6):965\u201371.","journal-title":"Am Heart J"},{"issue":"22","key":"825_CR12","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","volume":"42","author":"M Arnold","year":"2021","unstructured":"Arnold M, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;42(22):2186\u201396.","journal-title":"Eur Heart J"},{"issue":"1","key":"825_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","volume":"4","author":"PR Kamstrup","year":"2016","unstructured":"Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) levels, lpa risk genotypes, and increased risk of heart failure in the general population. Jacc-Heart Fail. 2016;4(1):78\u201387.","journal-title":"Jacc-Heart Fail"},{"issue":"12","key":"825_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11906-021-01161-6","volume":"23","author":"NC Ward","year":"2021","unstructured":"Ward NC, et al. Lipoprotein (a) and hypertension. Curr Hypertens Rep. 2021;23(12):9.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"825_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1399-0004.1997.tb04343.x","volume":"52","author":"E Papagrigorakis","year":"1997","unstructured":"Papagrigorakis E, et al. Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet. 1997;52(5):262\u201371.","journal-title":"Clin Genet"},{"issue":"20","key":"825_CR16","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/eurheartj\/ehx233","volume":"38","author":"A von Eckardstein","year":"2017","unstructured":"von Eckardstein A. Lipoprotein(a). Eur Heart J. 2017;38(20):1530\u20132.","journal-title":"Eur Heart J"},{"issue":"5","key":"825_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","volume":"57","author":"MB Boffa","year":"2016","unstructured":"Boffa MB, Koschinsky ML. thematic review series: lipoprotein (a): coming of age at last lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745\u201357.","journal-title":"J Lipid Res"},{"key":"825_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.thromres.2020.12.014","volume":"198","author":"DC Rijken","year":"2021","unstructured":"Rijken DC, et al. How significant is the antifibrinolytic effect of lipoprotein(a) for blood clot lysis? Thromb Res. 2021;198:210\u20132.","journal-title":"Thromb Res"},{"issue":"19","key":"825_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. Jama-J Am Med Assoc. 2017;318(19):1925\u20136.","journal-title":"Jama-J Am Med Assoc"},{"issue":"8","key":"825_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1371\/journal.pmed.0050177","volume":"5","author":"NA Sheehan","year":"2008","unstructured":"Sheehan NA, et al. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008;5(8):1205\u201310.","journal-title":"PLoS Med"},{"issue":"24","key":"825_CR21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.031912","volume":"137","author":"D Kamimura","year":"2018","unstructured":"Kamimura D, et al. Cigarette smoking and incident heart failure: insights from the jackson heart study. Circulation. 2018;137(24):2572\u201382.","journal-title":"Circulation"},{"issue":"5","key":"825_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/HCO.0000000000000205","volume":"30","author":"IE Albertsen","year":"2015","unstructured":"Albertsen IE, et al. Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics. Curr Opin Cardiol. 2015;30(5):512\u20137.","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"825_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amjmed.2012.11.024","volume":"126","author":"TF Overvad","year":"2013","unstructured":"Overvad TF, et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013;126(7):9.","journal-title":"Am J Med"},{"issue":"4","key":"825_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5551\/jat.57232","volume":"28","author":"M Takada","year":"2021","unstructured":"Takada M, et al. Body mass index and mortality from aortic aneurysm and dissection. J Atheroscler Thromb. 2021;28(4):338\u201348.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"825_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/euhj.2000.2469","volume":"22","author":"WD Ashton","year":"2001","unstructured":"Ashton WD, Nanchahal K, Wood DA. Body mass index and metabolic risk factors for coronary heart disease in women. Eur Heart J. 2001;22(1):46\u201355.","journal-title":"Eur Heart J"},{"issue":"5","key":"825_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/ijs.12168","volume":"9","author":"M Saini","year":"2014","unstructured":"Saini M, et al. Body mass index and acute ischemic stroke outcomes. Int J Stroke. 2014;9(5):618\u201323.","journal-title":"Int J Stroke"},{"issue":"12","key":"825_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00467-004-1588-8","volume":"19","author":"RF Robinson","year":"2004","unstructured":"Robinson RF, et al. Body mass index in primary and secondary pediatric hypertension. Pediatr Nephrol. 2004;19(12):1379\u201384.","journal-title":"Pediatr Nephrol"},{"key":"825_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.thromres.2020.05.014","volume":"192","author":"J Rahmani","year":"2020","unstructured":"Rahmani J, et al. Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: a systematic review and dose-response meta-analysis of cohort studies among four million participants. Thromb Res. 2020;192:64\u201372.","journal-title":"Thromb Res"},{"issue":"3","key":"825_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in mendelian randomization studies. Int J Epidemiol. 2011;40(3):755\u201364.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"825_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyq151","volume":"40","author":"BL Pierce","year":"2011","unstructured":"Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740\u201352.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"825_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/rheumatology\/keaa506","volume":"60","author":"YL Dan","year":"2021","unstructured":"Dan YL, et al. Circulating adiponectin levels and systemic lupus erythematosus: a two-sample mendelian randomization study. Rheumatology. 2021;60(2):940\u20136.","journal-title":"Rheumatology"},{"issue":"7","key":"825_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/aje\/kwt084","volume":"178","author":"BL Pierce","year":"2013","unstructured":"Pierce BL, Burgess S. Efficient design for mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177\u201384.","journal-title":"Am J Epidemiol"},{"key":"825_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0099-7","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018. https:\/\/doi.org\/10.1038\/s41588-018-0099-7.","journal-title":"Nat Genet"},{"issue":"8","key":"825_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1161\/01.ATV.15.8.1145","volume":"15","author":"T Freestone","year":"1995","unstructured":"Freestone T, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic-aneurysm. Arterioscler Thromb Vasc Biol. 1995;15(8):1145\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"825_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/oxfordjournals.eurheartj.a015314","volume":"18","author":"AJ Lee","year":"1997","unstructured":"Lee AJ, et al. Smoking, atherosclerosis and risk of abdominal aortic aneurysm. Eur Heart J. 1997;18(4):671\u20136.","journal-title":"Eur Heart J"},{"key":"825_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2017.10.017","volume":"268","author":"Y Kubota","year":"2018","unstructured":"Kubota Y, et al. Lipoprotein(a) and abdominal aortic aneurysm risk: the atherosclerosis risk in communities study. Atherosclerosis. 2018;268:63\u20137.","journal-title":"Atherosclerosis"},{"issue":"2","key":"825_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/0003319716637792","volume":"68","author":"K Kotani","year":"2017","unstructured":"Kotani K, et al. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: a systematic review and meta-analysis. Angiology. 2017;68(2):99\u2013108.","journal-title":"Angiology"},{"issue":"7","key":"825_CR38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, et al. Association of lpa variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies a mendelian randomization analysis. JAMA Cardiology. 2018;3(7):619\u201327.","journal-title":"JAMA Cardiology"},{"issue":"3","key":"825_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","volume":"79","author":"Y Kaiser","year":"2022","unstructured":"Kaiser Y, et al. Association of lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79(3):223\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"825_CR40","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12035-016-0346-9","volume":"55","author":"XW Hong","year":"2018","unstructured":"Hong XW, et al. Lipoprotein (a) as a predictor of early stroke recurrence in acute ischemic stroke. Mol Neurobiol. 2018;55(1):718\u201326.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"825_CR41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1194\/jlr.R053066","volume":"57","author":"JC van Capelleveen","year":"2016","unstructured":"van Capelleveen JC, van der Valk FM, Stroes ESG. Thematic review series: lipoprotein (a): coming of age at last current therapies for lowering lipoprotein (a). J Lipid Res. 2016;57(9):1612\u20138.","journal-title":"J Lipid Res"},{"issue":"9","key":"825_CR42","first-page":"18316","volume":"9","author":"WJ Li","year":"2016","unstructured":"Li WJ, et al. The prospective effect of lipoprotein(a) on new-onset atrial fibrillation in patients with chronic heart failure. Int J Clin Exp Med. 2016;9(9):18316\u201323.","journal-title":"Int J Clin Exp Med"},{"issue":"16","key":"825_CR43","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","volume":"79","author":"P Mohammadi-Shemirani","year":"2022","unstructured":"Mohammadi-Shemirani P, et al. elevated lipoprotein(a) and risk of atrial fibrillation an observational and mendelian randomization study. J Am Coll Cardiol. 2022;79(16):1579\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"825_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fcvm.2022.808605","volume":"9","author":"P Gressenberger","year":"2022","unstructured":"Gressenberger P, et al. Lipoprotein(a) and pulmonary embolism severity-a retrospective data analysis. Front Cardiovasc Med. 2022;9:6.","journal-title":"Front Cardiovasc Med"},{"issue":"29","key":"825_CR45","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1002\/sim.7442","volume":"36","author":"JR Thompson","year":"2017","unstructured":"Thompson JR, et al. Mendelian randomization incorporating uncertainty about pleiotropy. Stat Med. 2017;36(29):4627\u201345.","journal-title":"Stat Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00825-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00825-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00825-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T06:04:39Z","timestamp":1667109879000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00825-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00825-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}